PL2101877T3 - Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo - Google Patents

Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo

Info

Publication number
PL2101877T3
PL2101877T3 PL07857153T PL07857153T PL2101877T3 PL 2101877 T3 PL2101877 T3 PL 2101877T3 PL 07857153 T PL07857153 T PL 07857153T PL 07857153 T PL07857153 T PL 07857153T PL 2101877 T3 PL2101877 T3 PL 2101877T3
Authority
PL
Poland
Prior art keywords
gile
vivo
cell invasion
activity neutralization
blocks
Prior art date
Application number
PL07857153T
Other languages
English (en)
Inventor
Ana Martin-Villalba
Susanne Kleber
Benedikt Wiestler
Peter G Krammer
Christel Herold-Mende
Ignacio Sancho-Martinez
Original Assignee
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Univ Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Univ Heidelberg filed Critical Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Publication of PL2101877T3 publication Critical patent/PL2101877T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL07857153T 2006-12-28 2007-12-28 Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo PL2101877T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87736706P 2006-12-28 2006-12-28
EP07857153.6A EP2101877B1 (en) 2006-12-28 2007-12-28 Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo
PCT/EP2007/011461 WO2008080623A2 (en) 2006-12-28 2007-12-28 Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo

Publications (1)

Publication Number Publication Date
PL2101877T3 true PL2101877T3 (pl) 2013-11-29

Family

ID=39400900

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11190918T PL2428252T3 (pl) 2006-12-28 2007-12-28 Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo
PL07857153T PL2101877T3 (pl) 2006-12-28 2007-12-28 Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11190918T PL2428252T3 (pl) 2006-12-28 2007-12-28 Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo

Country Status (12)

Country Link
US (2) US9309320B2 (pl)
EP (2) EP2428252B1 (pl)
JP (2) JP5558828B2 (pl)
AU (1) AU2007341631B9 (pl)
CA (1) CA2673868C (pl)
CY (1) CY1116006T1 (pl)
DK (2) DK2101877T3 (pl)
ES (2) ES2523992T3 (pl)
PL (2) PL2428252T3 (pl)
PT (2) PT2101877E (pl)
SI (1) SI2428252T1 (pl)
WO (1) WO2008080623A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3321277B1 (en) 2007-07-10 2019-09-18 Apogenix AG Tnf superfamily collectin fusion proteins
EP2318441A2 (en) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
JP5844158B2 (ja) 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
JP5754740B2 (ja) * 2009-07-21 2015-07-29 クイーン メアリー アンド ウェストフィールド カレッジＱｕｅｅｎ Ｍａｒｙ ａｎｄ Ｗｅｓｔｆｉｅｌｄ Ｃｏｌｌｅｇｅ 細胞内薬物送達のためのｆａｓ（アポ−１，ｃｄ９５）標的化プラットフォーム
EP2322927A1 (en) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
CA2878992C (en) * 2012-07-18 2020-09-22 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms
US20140065655A1 (en) * 2012-09-05 2014-03-06 Scivax Corporation Screening method for substance acting on maintenance of epithelial properties of cell
CA2910332A1 (en) * 2013-04-29 2014-11-06 Apogenix Gmbh Method of diagnosing cancer
WO2014186878A1 (en) 2013-05-24 2014-11-27 Cashman Neil R Cell senescence markers as diagnostic and therapeutic targets
WO2015107105A1 (en) * 2014-01-15 2015-07-23 Apogenix Gmbh Method of predicting the responsiveness of a cancer disease to treatment on the basis of DNA methylation
WO2015165973A1 (en) * 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
CA3002745A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CA3123853A1 (en) * 2018-12-20 2020-06-25 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
US12516307B2 (en) 2020-08-18 2026-01-06 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
NO933860L (no) 1992-10-30 1994-05-02 Bristol Myers Squibb Co Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6060238A (en) 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
WO1996029350A1 (en) 1995-03-20 1996-09-26 Sumitomo Electric Industries, Ltd. MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME
CN1196733A (zh) 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
JPH09124509A (ja) 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
EP0965637B1 (en) 1996-05-02 2005-07-20 Mochida Pharmaceutical Co., Ltd. Fas ANTIGEN DERIVATIVES
WO1998010070A1 (en) 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. HUMANIZED IMMUNOGLOBULIN REACTING SPECIFICALLY WITH Fas LIGAND OR ACTIVE FRAGMENTS THEREOF AND REGION INDUCING APOPTOSIS ORIGINATING IN Fas LIGAND
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
ID27820A (id) 1998-03-30 2001-04-26 Lilly Co Eli APLIKASI-APLIKASI PENGOBATAN POLIPEPTIDA MATURE FLINT (mFLINT) ATAU OPG3, BAGIAN KELOMPOK SUPER RESEPTOR TNF
US6348573B1 (en) 1998-04-27 2002-02-19 The Regents Of The University Of Michigan Compositions and methods for identifying apoptosis signaling pathway inhibitors and activators
ATE391136T1 (de) 1998-06-18 2008-04-15 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
US20030170244A1 (en) * 2001-12-21 2003-09-11 Pluenneke John D. Inhibition of Fas signaling
WO2003088975A1 (en) * 2002-04-17 2003-10-30 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
HK1077592A1 (zh) * 2003-03-26 2006-02-17 Apogenix Gmbh 改进型fc融合蛋白质
WO2005107801A2 (en) * 2004-04-29 2005-11-17 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies

Also Published As

Publication number Publication date
EP2101877B1 (en) 2013-06-19
EP2428252B1 (en) 2014-11-05
PL2428252T3 (pl) 2015-04-30
DK2101877T3 (da) 2013-09-23
US9309320B2 (en) 2016-04-12
ES2420582T3 (es) 2013-08-26
CA2673868C (en) 2016-03-22
JP2010514722A (ja) 2010-05-06
US9850308B2 (en) 2017-12-26
ES2523992T3 (es) 2014-12-03
SI2428252T1 (sl) 2015-01-30
PT2101877E (pt) 2013-07-22
EP2101877A2 (en) 2009-09-23
PT2428252E (pt) 2014-12-11
US20160115236A1 (en) 2016-04-28
WO2008080623A2 (en) 2008-07-10
US20100322922A1 (en) 2010-12-23
JP2014167024A (ja) 2014-09-11
JP5893078B2 (ja) 2016-03-23
EP2428252A1 (en) 2012-03-14
CA2673868A1 (en) 2008-07-10
AU2007341631B2 (en) 2012-08-30
CY1116006T1 (el) 2017-01-25
AU2007341631B9 (en) 2012-10-04
JP5558828B2 (ja) 2014-07-23
DK2428252T3 (en) 2015-02-16
WO2008080623A3 (en) 2008-09-12
AU2007341631A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
PL2428252T3 (pl) Neutralizacja aktywności cd95 blokuje inwazję komórek glejaka in vivo
DE112006004268A5 (de) Elektrochemische Zelle
EP2212963A4 (en) ELECTROCHEMICAL CELL WITH QUASIPOLAR STRUCTURE
EP2005504A4 (en) ELECTROLYTE
BR112012014158A2 (pt) "célula eletroquímica"
BRPI0821042A2 (pt) Célula de lítio
DE602006015616D1 (de) Ionische polymerelektrolyte
PL1675207T3 (pl) Elektrolit strukturyzowany dla mikrobaterii
DK1891824T3 (da) Celleskift i cellulære netværk
PL2634242T3 (pl) Ulepszony sposób hodowli komórek
EP2094175A4 (en) SPINE CROSS CONNECTORS
EP2208248A4 (en) ELECTROCHEMICAL STORAGE CELL
DE602006001727D1 (de) Polymerbatteriepack
EP2028264A4 (en) CELL INCUBATOR
BRPI0809902A2 (pt) Métodos de avaliar células e culturas celulares
DK2027150T3 (da) Allo-begrænsede peptid-specifikke t-celler
BRPI0907886A2 (pt) Célula de lítio
BRPI0814572A2 (pt) Célula de lítio
BRPI0908722A2 (pt) reformadora ativa
EP1955394A4 (en) IONICALLY CONDUCTIVE SOUND SUPPLEMENT FOR USE IN ELECTROCHEMICAL CELLS
DE602006018404D1 (de) Batteriepack
EP1866998A4 (en) ELECTROCHEMICAL SECONDARY CELL
EP2210309A4 (en) BATTERY CELL WITH QUASI-BIPOLAR CONSTRUCTION
EP2104174A4 (en) LITHIUM SECONDARY BATTERY ION
EP1856248A4 (en) HOMOGENEOUS NEURALE CURRENT CELLS